- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- The NICE-Wide Prioritisation Board met on 20 November 2025 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due to cyclosporin being a generic, new of formulation of existing guidance TA369. Therefore, there would be no additional value in conducting a separate evaluation.
- ID number:
- 12293
Provisional Schedule
- Prioritisation board meeting:
- 20 December 2025
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
For further information on how we select topics for development, please see our page about topic prioritisation